Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2015
October 2015, Vol 6, No 9
October 2015, Vol 6, No 9
Value Proposition of Oncology Pharmaceuticals: Drug Manufacturers Increasing Focus on Patient Support
By
Wayne Kuznar
Value Propositions
,
Value Peer-spectives
October 2015, Vol 6, No 9
Washington, DC—Complex partnerships among cancer care stakeholders, including drug manufacturers, are becoming the norm.
Read Article
In the Literature - October 2015
In the Literature
October 2015, Vol 6, No 9
Read Article
Current Practice Least Cost-Effective Option in Prostate Cancer Management
By
Meg Barbor, MPH
Economics & Value
,
Economics of Cancer Care
October 2015, Vol 6, No 9
Copenhagen, Denmark—Current follow-up strategy for patients with prostate cancer was found to be the least cost-effective approach in an analysis conducted in Europe.
Read Article
Whole-Brain Radiotherapy for Brain Metastases Is Cost-Effective
By
Rosemary Frei, MSc
Economics & Value
,
Economics of Cancer Care
October 2015, Vol 6, No 9
The treatment of patients with brain metastases involves issues of controlling recurrence, side effects, and costs.
Read Article
Using Genetics to Guide Pembrolizumab Therapy in CRC
By
Dana Taylor
Emerging Therapies
,
Personalized Medicine
October 2015, Vol 6, No 9
The treatment of patients with colorectal cancer (CRC) may benefit from immunotherapy with anti–PD-1 agents, based on results of a recent study using pembrolizumab (Keytruda).
Read Article
NEXT Study: Biosimilar Filgrastim an Effective Alternative for Chemotherapy-Induced Neutropenia
By
Meg Barbor, MPH
Emerging Therapies
,
Personalized Medicine
,
Biosimilars
October 2015, Vol 6, No 9
Copenhagen, Denmark—Biosimilar filgrastim (Nivestim; Hospira), which was approved earlier this year by the European Commission but not yet by the FDA, showed effectiveness for the treatment of neutropenia and febrile neutropenia (FN) in patients undergoing cytotoxic chemotherapy for solid tumors and hematologic malignancies, according to a study presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology meeting.
Read Article
Atezolizumab: Another Immunotherapy for Lung Cancer?
By
Phoebe Starr
Emerging Therapies
,
Immunotherapy
,
Personalized Medicine
October 2015, Vol 6, No 9
Vienna, Austria—Immunotherapy is poised to become a game changer for patients with non–small-cell lung cancer (NSCLC).
Read Article
ASCO’s Value Framework: Is It All About the Drugs?
By
Avi Dor, PhD
;
Elizabeth Hoffler, MSW
;
Mandi Pratt-Chapman, MA
;
Eduardo Sotomayor, MD
Value in Oncology
,
ASCO’s Value Framework
October 2015, Vol 6, No 9
The American Society of Clinical Oncology (ASCO) recently issued its framework to assess the value of cancer treatment options in response to the major challenge of escalating healthcare costs in the United States.
Read Article
FDA News - October 2015
FDA Approvals, News & Updates
,
In the News
October 2015, Vol 6, No 9
Read Article
An Accountable Payment Model a “Win-Win-Win” Solution to Value-Based Care
By
Wayne Kuznar
Economics & Value
,
Value-Based Care
October 2015, Vol 6, No 9
The Triple Aim of better patient care, lower spending by payers, and the maintenance of financially viable practices and hospitals is achievable with condition-based payment models in oncology, said Harold D. Miller, MS, President and Chief Executive Officer, Center for Healthcare Quality and Payment Reform, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma